Posted 21 April 2015 - 07:13 AM
CML guidelines highlight need for TKI switch timing, choice
By Lynda Williams, Senior medwireNews Reporter
20 April 2015
"Second-line treatment following first-line toxicity can consist of any alternative TKI. Following resistance to imatinib, patients should switch to another TKI, such as dasatinib, nilotinib, bosutinib or ponatinib. From nilotinib, patients should switch to dasatinib, bosutinib or ponatinib, whereas patients with dasatinib resistance should be given nilotinib, bosutinib or ponatinib."
A goal of treatment is to lead to treatment free remission (TFR). TFR is a goal for second line TKI's for patients who achieve rapid and deep molecular remission.
Diagnosed 11 May 2011 (100% FiSH, 155% PCR)
with b2a2 BCR-ABL fusion transcript coding for the 210kDa BCR-ABL protein
Sprycel: 20 mg per day - taken at lights out with Quercetin and/or Magnesium Taurate
6-8 grams Curcumin C3 complex.
2015 PCR: < 0.01% (M.D. Anderson scale)
2016 PCR: < 0.01% (M.D. Anderson scale)
March 2017 PCR: 0.01% (M.D. Anderson scale)
June 2017 PCR: "undetected"
September 2017 PCR: "undetected"